![](http://investorshub.advfn.com/images/default_ih_profile2_4848.jpg?cb=0)
Monday, June 05, 2017 9:56:47 AM
Michael Castagna-
"Entrepreneurial executive with more than 20 years of experience in marketing, sales, medical affairs and strategic development in Fortune 500 companies as well as privately held biotech start-ups. Proven pre-launch and launch experience on over 15 brands in seven distinct disease states with global sales ranging from $250M to over $2Billion. Disciplined, results-driven leader with a personal commitment to developing people and working cross-functionally to achieve core objectives in highly complex and competitive disease states. Specialty disease state expertise: Oncology, Nephrology, GI, Psoriasis, HIV, Hepatitis B & C, Endocrinology, Rheumatoid Arthritis and Infertility."
"Specialties: Strategy, Marketing, Pricing, Managed Care, Clinical Knowledge, Leadership, Generic Industry, Biosimilars, Turn Around and Launch Experience"
Compared to:
Mathew Pfeffer-
"Seasoned financial executive with over 30 years experience, including three public company CFO positions, public company board positions and in-depth knowledge of financing strategies for public companies. Active CPA accreditation and over $1 billion raised to date through well-established Wall Street network."
"Strengths: Strategic planning, mergers and reorganizations (including spin-outs), team building, communications, technical accounting, creative financing"
Recent MNKD News
- INHALE-3 Study Reveals Positive Readout in Head-to-Head Comparison of Inhaled Insulin vs. Usual Care in T1D; New Data Presented at American Diabetes Association’s 84th Scientific Sessions • GlobeNewswire Inc. • 06/22/2024 12:00:00 PM
- Inhale-3 Study Results to be Presented During a 90-Minute Symposium on Saturday, June 22 at the American Diabetes Association’s 84th Scientific Sessions • GlobeNewswire Inc. • 06/05/2024 10:45:00 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 05/30/2024 01:00:03 AM
- MannKind to Establish Boston-Area Research & Development Foothold and Expand Portfolio of Dry Powder Inhalation Technology in Transaction With Pulmatrix • GlobeNewswire Inc. • 05/29/2024 12:45:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 05/22/2024 01:00:31 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 05/22/2024 01:00:25 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 05/22/2024 01:00:19 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 05/22/2024 01:00:13 AM
- Form 144 - Report of proposed sale of securities • Edgar (US Regulatory) • 05/21/2024 08:09:54 PM
- Form 144 - Report of proposed sale of securities • Edgar (US Regulatory) • 05/21/2024 08:07:43 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 05/18/2024 01:36:29 AM
Glidelogic Corp. Becomes TikTok Shop Partner, Opening a New Chapter in E-commerce Services • GDLG • Jul 5, 2024 7:09 AM
Freedom Holdings Corporate Update; Announces Management Has Signed Letter of Intent • FHLD • Jul 3, 2024 9:00 AM
EWRC's 21 Moves Gaming Studios Moves to SONY Pictures Studios and Green Lights Development of a Third Upcoming Game • EWRC • Jul 2, 2024 8:00 AM
BNCM and DELEX Healthcare Group Announce Strategic Merger to Drive Expansion and Growth • BNCM • Jul 2, 2024 7:19 AM
NUBURU Announces Upcoming TV Interview Featuring CEO Brian Knaley on Fox Business, Bloomberg TV, and Newsmax TV as Sponsored Programming • BURU • Jul 1, 2024 1:57 PM
Mass Megawatts Announces $220,500 Debt Cancellation Agreement to Improve Financing and Sales of a New Product to be Announced on July 11 • MMMW • Jun 28, 2024 7:30 AM